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OBJECTIVES: To explore the impact of Dupuytren’s Disease (DD) on patients’ qual-
ity of life (QoL) and identify implications for clinical practice. A search of the liter-
ature failed to identify a patient-reported outcome measure for assessing the im-
pact of DD. The study was designed to be the first stage in the development of such
a measure. METHODS: The needs-based model of QoL was adopted and unstruc-
tured qualitative interviews were conducted with DD patients attending out-pa-
tients clinics. Data were transcribed and then underwent interpretative phenom-
enological analysis (IPA) to identify the key impact areas and common themes in
individuals’ personal experiences. RESULTS: Thirty-four DD patients (73.5% male;
aged 41-80; mean (SD): 64.2 (12.5) years) were interviewed. The sample had a wide
range of duration of DD (0.5-40; mean (SD) 12.6 (9.9) years). A total of 953 statements
relating to the impact of DD were identified from the interview transcripts. These
statements fell into 3 major categories of impact; emotional impairment (4 themes
including having no confidence in hand and being embarrassed), activity limita-
tions (10 themes including dressing, gripping and personal care) and QoL (11
themes including avoiding physical contact, self-consciousness and socialisation).
CONCLUSIONS: Dupuytren’s disease impacts on patients in three main areas;
emotional reactions, activity limitations and QoL. In any trial designed to deter-
mine the benefits of new interventions for the disease it is important to ensure that
each of these areas is assessed. It is intended to develop valid and reliable DD-
specific scales to cover each of these outcomes.
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OBJECTIVES: Rheumatoid arthritis (RA) has been associated with significant de-
creases in a patient’s health-related quality of life (HRQL). Our objective was to
measure the HRQL of Greek RA patients treated with adalimumab. These outcomes
were assessed for differences between the results of a generic (EuroQol-5 Dimen-
sion [EQ-5D]) and an RA disease–specific (Health Assessment Questionnaire [HAQ])
instrument. METHODS: Data were drawn from an observational 52-week, single-
arm study that measured the effectiveness of adalimumab in the treatment of
patients with moderate to severe RA. Two instruments were implemented for re-
cording the HRQL during the study duration, the EQ-5D and the HAQ. All statistical
analysis was performed using SPSS software. RESULTS: The outcome measures
revealed that adalimumab is effective in treating patients with moderate to severe
RA. The mean utility score, as indicated by the EQ-5D questionnaire, increased
from 0.433 at baseline to 0.621 after 12 months of treatment. The mean disability
index, as indicated by the HAQ, decreased from 1.341 at baseline to 0.624 at the end
of treatment. Although both instruments reached the same conclusion, there was
only moderate correlation between the instruments (Spearman’s correlation at
baseline and at 12 months, r0.659 and r0.793, respectively). As expected, the
HAQ was more closely correlated with disease activity measures (swollen and
tender joints, visual analog scale [VAS] for pain assessment, and VAS for general
health assessment by both the patient and the physician) than the EQ-5D
questionnaire. CONCLUSIONS: Adalimumab is effective in the treatment of Greek
patients with moderate to severe RA. Caution should be taken in interpreting the
changes in HRQL when different outcome measures are used.
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OBJECTIVES:Determine whether treatments with Unhais da Serra natural mineral
water, a Portuguese spa, are effective in low back pain for spondylarthrosis.
METHODS: A descriptive, longitudinal, observational, uncontrolled prospective
study was conducted. The 51 study participants underwent 14 days of treatment
with Unhais da Serra natural mineral water. Assessment criteria were: pain inten-
sity (Visual Analogue Scale), quality of life (SF36v2), disability (ODIv2), absenteeism,
acute outbreak/relapse, drug consumption. The evaluation was conducted in four
distinct stages: the first day before, 14 days, 3 and 6 months after the thermal
treatment. RESULTS: The mean age of the sample was 60.53 years, 60.8% were
female. The duration of illness was, on average, 7.35 years, 50.9% were retired and
90.2% were from a countryside district. There was a statistically significant im-
provement (p 0.05) in pain intensity, quality of life, disability, absenteeism and
drug consumption, 14 days, 3 and 6 months after thermal treatment compared to
baseline. There was no effect on the number of acute outbreak/relapse. Regarding
socio-demographic and clinical data, we get no consistent results, only low corre-
lations and some differences in just a few moments of assessment.CONCLUSIONS:
This research showed that 14 days of treatment with natural mineral water of
Unhais da Serra spa, reduced pain, disability and drug consumption, improved
quality of life, not influencing the number of outbreaks acute/relapse presented by
the participants. All the beneficial effects were observed in the short and medium
term (six months). No consistent conclusion could be drawn to the possible influ-
ence of socio-demographic and clinical variables. Thus, treatment with Unhais da
Serra spa shows up as an effective complementary treatment modality in selected
patients with lumbar spondylarthrosis. It seems to be justified and useful to famil-
iarize patients and their physicians with this modality of treatment because the
socio-economic impact of the pathology.
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OBJECTIVES: Duloxetine is approved for the treatment of major depressive disor-
der (MDD) and general anxiety disorder (GAD), and for the management of diabetic
peripheral neuropathic pain (DPNP), fibromyalgia (FM), and chronic musculoskel-
etal pain, as studied in patients with osteoarthritis (OA) and chronic low back pain.
This study assessed pain medication use prior to duloxetine initiation among pa-
tients with each of these conditions. METHODS: US administrative claims were
used to identify commercially-insured duloxetine initiators 1/1/2009-3/31/2010
who had any of the 6 medical conditions mentioned above during the 12 months
prior to duloxetine initiation (defined as no duloxetine pill coverage in the previous
90 days). Utilization of pain medications including antidepressants, anticonvul-
sants, opioids, non-steroidal anti-inflammatory drugs (NSAIDs), and muscle relax-
ants was assessed over the 3, 6 and 12 months prior to duloxetine initiation.
RESULTS: The study identified 19,546, 5,764, 2,334, 15,362, 12,317, and 27,781 du-
loxetine initiators in the MDD, GAD, DPNP, FM, OA, and low back pain (LBP) groups.
Antidepressant use was high across all conditions over the 12 months prior to
initiation, especially among patients with MDD (84.4%) or GAD (79.9%). Anticonvul-
sant utilization was highest in DPNP (63.1%) and FM (51.9%), lowest in GAD (39.5%),
and similar among other groups (range: 42.8%-48.3%). Opioid use varied greatly
across groups (54.5-81.6%), with the lowest use among GAD patients and the high-
est use among LBP patients. GAD patients had the lowest NSAID use (32.9%), while
OA patients had the highest utilization (58.1%). The use of muscle relaxants ranged
between 29.4% (DPNP) and 56.7% (LBP) at 12 months prior to duloxetine initiation.
Pain medication use in the prior 3 and 6 months showed similar trends.
CONCLUSIONS: Patients used several types of pain medications prior to initiating
duloxetine across disease states. The trends in use were consistent 3, 6, and 12
months prior to duloxetine initiation.
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OBJECTIVES: Osteoporosis represents a significant burden both to patients that
suffers from this condition, given the complications associated with this disease,
as well as to the health care system, given the elevated costs to treat this condi-
tions. Different options are considered in the treatment of osteoporosis, but there
are scanty assessments of this condition in large populations. The objective of this
study is to describe the population patterns of the prevalence of this disease as well
as main treatment trends in primary care centres (PCC) in Madrid. METHODS:
Information was gathered from electronic medical records of PCC of 7 areas of the
region of Madrid. Cross-sectional descriptive study from PCC database. This data-
base contains information about 1,318,020 patients who have visited PCC during
2006 and are older than 25 years-old. Patients with diagnosis of osteoporosis have
been identified. The use of pharmacological interventions (biphosphonate, ralox-
ifene, calcium) are described and compared considering sex, age, weight, height,
comorbidity, concomitant treatments, number of visits to the doctor and other
sociodemographic aspects. RESULTS: Overall, the prevalence of osteoporosis was
4.4%, being women 89.3% of reported cases. The median age was 64 years-old
(interquartile range 73-57). Osteoporotic patients used biphosphonates (33.1%),
raloxifene (3.29%), calcium (40,3%). A 14,3% of patients used only calcium. A 45.31%
of patients did not use calcium or other pharmacological treatments. The median
age of patients who used biphosphonates was 67, whereas the median age of
patients who did not use any treatment, including calcium, was 61. A 7.0% of
patients were referred to the traumatologist. CONCLUSIONS: Different treatment
strategies are considered among physicans of PCC in Spain to manage osteoporotic
patients. A relevant proportion of patients did not use any pharmacological inter-
vention. The treatment strategies used in osteoporosis seem to vary by age, and
should be adapted to individual risk factors.
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OBJECTIVES: Duloxetine is approved to treat major depressive disorder (MDD) and
general anxiety disorder (GAD), and to manage the symptoms of diabetic periph-
eral neuropathic pain (DPNP), fibromyalgia (FM), and chronic musculoskeletal pain
as studied in patients with osteoarthritis (OA) and chronic low back pain. This
study assessed use of pain medications prior to duloxetine initiation among elderly
patients with each of these conditions. METHODS: Duloxetine initiators aged 65
with Medicare Supplemental Insurance in 2007, 2008 and during January 1, 2009-
March 31, 2010 who had any of the 6 medical conditions listed above during the 12
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